Table 3 Summary of reports on GLP-1RA use in transplant patients
From: Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases
Number of cases | Number of cases of RTx | Age (years) mean ± SD or (Me and range) | Sex male/female | eGFR (ml/min/1.73 m2) Baseline changes after GLP-1RA | HbA1c (%) Baseline changes after GLP-1RA | Body weight (kg) Baseline changes after GLP-1RA | References |
|---|---|---|---|---|---|---|---|
7 | 7 | N.A | N.A | 67.7 ± 18.7 73.9 ± 20.2 | 8.1 ± 0.8 | 78.0 ± 7.8 77.7 ± 9.1 | [26] |
63 | 51 | 58 (30–74) | 43/20 | M 47.1 M 42.4 | M 7.6 M 7.6 | M 98.7 M 99.5 | [27] |
L 63 D 25 | L 51 D 21 | L 58 (30–74) D 57 (35–76) | N.A | L/DMe 48.0/42.5 L/DMe 55.2/39.1 | L/D Me 7.5/7.5 L/D Me 6.9/7.7 | L/D Me 98.9/112.6 L/D Me 93.8/111.6 | [28] |
14 | 14 | 51.8 (40.4–62.2) | 11/3 | 53 (40.2–60) 56 (44.7–67) | 7.7 (6.8–8.1) 7.1 (6.2–7.8) | 106.6 (98.5–125.2) 97.2 (95.2–119.7) | [29] |
19 | 7 | 62 (48–71) | 12/7 | Change from baseline to 12 months + 1.08 | Change from baseline to 12 months − 0.75 | Change from baseline to 12 months − 4.86 | [30] |